-+ 0.00%
-+ 0.00%
-+ 0.00%

Upstream Bio to present Phase 2 VIBRANT verekitug data at ATS 2026 conference

PUBT·04/17/2026 11:01:52
Listen to the news
Upstream Bio to present Phase 2 VIBRANT verekitug data at ATS 2026 conference
  • Upstream Bio scheduled new Phase 2 VIBRANT trial data for verekitug in chronic rhinosinusitis with nasal polyps for presentation at ATS 2026 on May 18, 2026.
  • Posters will cover clinical effects in patients with comorbid asthma, signaling potential positioning in a higher-need subgroup.
  • Separate analyses will outline verekitug impact on nasal and blood biomarkers, supporting its profile as a TSLP receptor antagonist in development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604170700PRIMZONEFULLFEED9691855) on April 17, 2026, and is solely responsible for the information contained therein.